Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Summary
Merck and Moderna revealed that their customized mRNA vaccine significantly lowered the risk of death or cancer return in advanced skin cancer patients. The treatment outperformed standard care in a recent late-stage clinical study. Consequently, the pharmaceutical partners are now discussing potential approval with regulatory agencies.
Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical partners Merck and Moderna announced Thursday. The results are a significant advance in melanoma treatment; Merck and Moderna are already engaging with regulatory authorities to get the vaccine approved. More broadly, the…
Source: Read the full story at Ars Technica - All content